RU2018121290A - Комбинации лизина бактериофага и антибиотика против грам-положительных бактерий - Google Patents
Комбинации лизина бактериофага и антибиотика против грам-положительных бактерий Download PDFInfo
- Publication number
- RU2018121290A RU2018121290A RU2018121290A RU2018121290A RU2018121290A RU 2018121290 A RU2018121290 A RU 2018121290A RU 2018121290 A RU2018121290 A RU 2018121290A RU 2018121290 A RU2018121290 A RU 2018121290A RU 2018121290 A RU2018121290 A RU 2018121290A
- Authority
- RU
- Russia
- Prior art keywords
- identity
- binding
- domain
- seq
- antibiotic
- Prior art date
Links
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 title claims 16
- 239000004472 Lysine Substances 0.000 title claims 16
- 239000003242 anti bacterial agent Substances 0.000 title claims 9
- 241000192125 Firmicutes Species 0.000 title claims 4
- 229940088710 antibiotic agent Drugs 0.000 title claims 4
- 241001515965 unidentified phage Species 0.000 title 1
- 230000003115 biocidal effect Effects 0.000 claims 28
- 230000003197 catalytic effect Effects 0.000 claims 27
- 241000194017 Streptococcus Species 0.000 claims 20
- 102000037865 fusion proteins Human genes 0.000 claims 20
- 108020001507 fusion proteins Proteins 0.000 claims 20
- 241000191940 Staphylococcus Species 0.000 claims 19
- 238000000034 method Methods 0.000 claims 19
- 230000009089 cytolysis Effects 0.000 claims 18
- 229920001184 polypeptide Polymers 0.000 claims 17
- 108090000765 processed proteins & peptides Proteins 0.000 claims 17
- 102000004196 processed proteins & peptides Human genes 0.000 claims 17
- 150000001413 amino acids Chemical group 0.000 claims 9
- 241000894006 Bacteria Species 0.000 claims 6
- 108010013198 Daptomycin Proteins 0.000 claims 4
- 101000925662 Enterobacteria phage PRD1 Endolysin Proteins 0.000 claims 4
- DOAKLVKFURWEDJ-QCMAZARJSA-N daptomycin Chemical compound C([C@H]1C(=O)O[C@H](C)[C@@H](C(NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@H](C(=O)N1)[C@H](C)CC(O)=O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CCCCCCCCC)C(=O)C1=CC=CC=C1N DOAKLVKFURWEDJ-QCMAZARJSA-N 0.000 claims 4
- 229960005484 daptomycin Drugs 0.000 claims 4
- 108010059993 Vancomycin Proteins 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 229960003907 linezolid Drugs 0.000 claims 2
- TYZROVQLWOKYKF-ZDUSSCGKSA-N linezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CCOCC1 TYZROVQLWOKYKF-ZDUSSCGKSA-N 0.000 claims 2
- 229960003165 vancomycin Drugs 0.000 claims 2
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 claims 2
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 claims 2
- 241000191967 Staphylococcus aureus Species 0.000 claims 1
- 239000013060 biological fluid Substances 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
- A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/503—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01017—Lysozyme (3.2.1.17)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Paints Or Removers (AREA)
- Enzymes And Modification Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261644944P | 2012-05-09 | 2012-05-09 | |
| US61/644,944 | 2012-05-09 | ||
| US201261737239P | 2012-12-14 | 2012-12-14 | |
| US61/737,239 | 2012-12-14 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014149351A Division RU2659208C2 (ru) | 2012-05-09 | 2013-05-09 | Комбинации лизина бактериофага и антибиотика против грам-положительных бактерий |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2018121290A true RU2018121290A (ru) | 2019-03-06 |
Family
ID=49551273
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018121290A RU2018121290A (ru) | 2012-05-09 | 2013-05-09 | Комбинации лизина бактериофага и антибиотика против грам-положительных бактерий |
| RU2014149351A RU2659208C2 (ru) | 2012-05-09 | 2013-05-09 | Комбинации лизина бактериофага и антибиотика против грам-положительных бактерий |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014149351A RU2659208C2 (ru) | 2012-05-09 | 2013-05-09 | Комбинации лизина бактериофага и антибиотика против грам-положительных бактерий |
Country Status (16)
| Country | Link |
|---|---|
| US (5) | US10813983B2 (https=) |
| EP (2) | EP2849782B1 (https=) |
| JP (4) | JP6608697B2 (https=) |
| KR (3) | KR102310387B1 (https=) |
| CN (1) | CN104736172A (https=) |
| AU (3) | AU2013259512B2 (https=) |
| BR (1) | BR112014027842A2 (https=) |
| CA (1) | CA2872902A1 (https=) |
| DK (1) | DK2849782T3 (https=) |
| ES (1) | ES2784136T3 (https=) |
| HK (1) | HK1211484A1 (https=) |
| IL (3) | IL308477A (https=) |
| IN (1) | IN2014MN02437A (https=) |
| MX (2) | MX389127B (https=) |
| RU (2) | RU2018121290A (https=) |
| WO (1) | WO2013170015A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2018121290A (ru) | 2012-05-09 | 2019-03-06 | Контрафект Корпорейшн | Комбинации лизина бактериофага и антибиотика против грам-положительных бактерий |
| BR112014027818B1 (pt) | 2012-05-09 | 2023-03-28 | Contrafect Corporation | Usos de composições compreendendo polipeptídeo de lisina para prevenção, ruptura ou tratamento de um biofilme bacteriano |
| WO2015200783A2 (en) * | 2014-06-26 | 2015-12-30 | The Rockefeller University | Acinetobacter lysins |
| WO2016142445A2 (en) * | 2015-03-12 | 2016-09-15 | Micreos Human Health B.V. | A method of treatment of a bacterial infection |
| EP4115897A1 (en) * | 2015-09-17 | 2023-01-11 | Contrafect Corporation | Use of lysin to restore/augment antibacterial activity in the presence of pulmonary surfactant of antibiotics inhibited thereby |
| EP3454888B1 (en) * | 2016-05-12 | 2021-02-24 | Contrafect Corporation | Broth microdilution method for evaluating and determining minimal inhibitory concentration of antibacterial polypeptides |
| CA3067542A1 (en) | 2017-06-19 | 2018-12-27 | Syddansk Universitet | Bacitracin and/or daptomycin combined with cannabidiol for treatment of bacterial infections |
| US20220023399A1 (en) * | 2017-07-10 | 2022-01-27 | Contrafect Corporation | Blood component potentiation of lytic protein anti-bacterial activity and methods and uses thereof |
| BR112020017219A2 (pt) * | 2018-02-26 | 2020-12-22 | Contrafect Corporation | Lisinas plyss2 modificadas e usos das mesmas |
| BR112020026267A2 (pt) * | 2018-06-22 | 2021-04-06 | Contrafect Corporation | Lisinas e seus derivados resensibilizam novamente staphylococcus aureus e bactérias gram-positivas aos antibióticos |
| CN109668873B (zh) * | 2018-12-05 | 2021-03-16 | 山东恒业生物技术有限公司 | 一种活载体疫苗活性检测装置及其使用方法 |
| MX2021009389A (es) | 2019-02-05 | 2021-11-17 | Elanco Us Inc | Lactobacillus modificado geneticamente y usos del mismo. |
| JP2022525914A (ja) * | 2019-03-22 | 2022-05-20 | コントラフェクト コーポレイション | 感染性心内膜炎を治療する方法 |
| WO2020210691A1 (en) * | 2019-04-11 | 2020-10-15 | Contrafect Corporation | Method of treating and preventing bone and joint infections |
| CN119837855A (zh) * | 2019-12-19 | 2025-04-18 | 乔治亚州大学研究基金会 | 用于治疗细菌感染和增强抗生素的化合物 |
| US20230277632A1 (en) * | 2020-05-19 | 2023-09-07 | Contrafect Corporation | MODIFIED PlySs2 LYSINS AND ANTIBIOTIC COMBINATIONS FOR USE AGAINST GRAM-POSITIVE BACTERIA |
| RU2755817C1 (ru) * | 2020-07-22 | 2021-09-21 | Федеральное Государственное бюджетное научное учреждение "Федеральный научный центр биологических систем и агротехнологий российской академии наук" | Способ снижения грамположительной микрофлоры в кишечнике птицы |
| KR102528412B1 (ko) * | 2020-09-08 | 2023-05-04 | 클립스비엔씨 주식회사 | 신규한 포도상구균 감염 질환의 예방 또는 치료용 조성물 |
| WO2022261360A1 (en) * | 2021-06-09 | 2022-12-15 | Contrafect Corporation | Plyss2 lysins and variants thereof for use against multidrug resistant gram-positive bacteria |
| CN115105491B (zh) * | 2022-07-08 | 2023-12-22 | 东北农业大学 | 丝氨酸在制备抑制猪链球菌药物中的用途 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU8108587A (en) | 1986-10-08 | 1988-05-06 | David Bernstein | Method for exposing group a streptococcal antigens and an improved diagnostic test for the identification of group a streptococci |
| CA1315229C (en) | 1987-06-10 | 1993-03-30 | Eli Lilly And Company | Chromatographic purification process |
| EP0895534A1 (en) * | 1996-04-15 | 1999-02-10 | Nymox Corporation | Compositions containing bacteriophages and methods of using bacteriophages to treat infections |
| US6248324B1 (en) | 1997-10-31 | 2001-06-19 | Vincent Fischetti | Bacterial phage associated lysing enzymes for treating dermatological infections |
| US6264945B1 (en) | 1997-10-31 | 2001-07-24 | Vincent A Fischetti | Parenteral use of bacterial phage associated lysing enzymes for the therapeutic treatment of bacterial infections |
| US6254866B1 (en) | 1997-10-31 | 2001-07-03 | New Horizons Diagnostics Corporation | Use of phage associated lytic enzymes for treating bacterial infections of the digestive tract |
| US5997862A (en) | 1997-10-31 | 1999-12-07 | New Horizons Diagnostics Corporation | Therapeutic treatment of group A streptococcal infections |
| US20060292135A1 (en) | 1997-10-31 | 2006-12-28 | Lawrence Loomis | Use of bacterial phage-associated lysing proteins for preventing and treating bacterial infections in humans, animals and fowl |
| AU2876799A (en) | 1999-02-25 | 2000-09-14 | New Horizons Diagnostics, Inc. | A means for the prophylactic and therapeutic treatment of streptococcal infections |
| US6056955A (en) | 1999-09-14 | 2000-05-02 | Fischetti; Vincent | Topical treatment of streptococcal infections |
| US6444813B2 (en) | 2000-02-02 | 2002-09-03 | Pharmacia & Upjohn Company | Linezolid-crystal form II |
| JP2006513149A (ja) | 2002-05-17 | 2006-04-20 | ニュー ホライゾンズ ディアグノスティックス コーポレイション | Ｂａｃｉｌｌｕｓａｎｔｈｒａｃｉｓを迅速かつ特異的に検出および殺滅するファージ関連溶菌酵素の同定 |
| US7569223B2 (en) | 2004-03-22 | 2009-08-04 | The Rockefeller University | Phage-associated lytic enzymes for treatment of Streptococcus pneumoniae and related conditions |
| EP1744779A2 (en) * | 2004-03-24 | 2007-01-24 | The Rockfeller University | Lytic enzymes and spore surface antigen for detection and treatment of "bacillus anthracis" bacteria and spores |
| US8389469B2 (en) | 2005-06-06 | 2013-03-05 | The Rockefeller University | Bacteriophage lysins for Bacillus anthracis |
| US7582291B2 (en) | 2005-06-30 | 2009-09-01 | The Rockefeller University | Bacteriophage lysins for Enterococcus faecalis, Enterococcus faecium and other bacteria |
| EP2360248A1 (en) | 2005-08-24 | 2011-08-24 | The Rockefeller University | Ply-GBS mutant lysins |
| WO2009029192A1 (en) | 2007-08-24 | 2009-03-05 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Surfactant-based antimicrobial solution for inhalation |
| WO2010002959A2 (en) * | 2008-07-03 | 2010-01-07 | The Rockefeller University | A chimeric bacteriophage lysin with activity against staphylococci bacteria |
| KR101016918B1 (ko) | 2009-01-08 | 2011-02-25 | 주식회사 인트론바이오테크놀로지 | 박테리아 특이적 넓은 항균 활성을 갖는 신규한 리신 단백질 |
| EP2539446B1 (en) | 2010-01-25 | 2017-11-01 | Alere Scarborough Inc. | A25 bacteriophage lysin |
| US20120271770A1 (en) * | 2011-04-20 | 2012-10-25 | Visa International Service Association | Managing electronic tokens in a transaction processing system |
| EP2699689A4 (en) | 2011-04-21 | 2014-12-17 | Univ Utrecht Holding Bv | STREPTOCOCCUS BACTERIOPHAGEN LYSINE FOR THE TREATMENT OF GRAM-POSITIVE BACTERIA IN PETS AND UTILITIES |
| DK2699253T3 (en) | 2011-04-21 | 2018-07-16 | Univ Rockefeller | STREPTOCOCCUS BACTERYPHAGIC LYSINES FOR THE DETECTION AND TREATMENT OF GRAM POSITIVE BACTERIES |
| WO2012145693A1 (en) | 2011-04-22 | 2012-10-26 | Rks Design, Inc. | Instrument retention assembly |
| EP2702070B1 (en) | 2011-04-27 | 2015-09-30 | Lysando AG | New antimicrobial agents |
| BR112014027818B1 (pt) | 2012-05-09 | 2023-03-28 | Contrafect Corporation | Usos de composições compreendendo polipeptídeo de lisina para prevenção, ruptura ou tratamento de um biofilme bacteriano |
| RU2018121290A (ru) | 2012-05-09 | 2019-03-06 | Контрафект Корпорейшн | Комбинации лизина бактериофага и антибиотика против грам-положительных бактерий |
-
2013
- 2013-05-09 RU RU2018121290A patent/RU2018121290A/ru unknown
- 2013-05-09 BR BR112014027842A patent/BR112014027842A2/pt not_active IP Right Cessation
- 2013-05-09 IN IN2437MUN2014 patent/IN2014MN02437A/en unknown
- 2013-05-09 MX MX2014013586A patent/MX389127B/es unknown
- 2013-05-09 EP EP13787128.1A patent/EP2849782B1/en active Active
- 2013-05-09 RU RU2014149351A patent/RU2659208C2/ru active
- 2013-05-09 WO PCT/US2013/040329 patent/WO2013170015A1/en not_active Ceased
- 2013-05-09 IL IL308477A patent/IL308477A/en unknown
- 2013-05-09 DK DK13787128.1T patent/DK2849782T3/da active
- 2013-05-09 US US14/399,575 patent/US10813983B2/en not_active Expired - Fee Related
- 2013-05-09 KR KR1020147034614A patent/KR102310387B1/ko not_active Expired - Fee Related
- 2013-05-09 IL IL235527A patent/IL235527B2/en unknown
- 2013-05-09 CA CA2872902A patent/CA2872902A1/en active Pending
- 2013-05-09 JP JP2015511698A patent/JP6608697B2/ja not_active Expired - Fee Related
- 2013-05-09 KR KR1020237023634A patent/KR20230113404A/ko not_active Withdrawn
- 2013-05-09 HK HK15112347.8A patent/HK1211484A1/xx unknown
- 2013-05-09 ES ES13787128T patent/ES2784136T3/es active Active
- 2013-05-09 CN CN201380036510.8A patent/CN104736172A/zh active Pending
- 2013-05-09 KR KR1020217031525A patent/KR20210121313A/ko not_active Ceased
- 2013-05-09 AU AU2013259512A patent/AU2013259512B2/en not_active Ceased
- 2013-05-09 EP EP20158873.8A patent/EP3685851A1/en active Pending
- 2013-06-04 US US13/909,618 patent/US9889181B2/en not_active Expired - Fee Related
-
2014
- 2014-11-07 MX MX2021011843A patent/MX2021011843A/es unknown
-
2017
- 2017-12-20 US US15/848,886 patent/US20180221456A1/en not_active Abandoned
-
2018
- 2018-04-24 AU AU2018202845A patent/AU2018202845B2/en not_active Ceased
- 2018-04-27 JP JP2018086685A patent/JP2018138045A/ja not_active Withdrawn
-
2019
- 2019-12-06 JP JP2019221319A patent/JP2020054370A/ja active Pending
-
2020
- 2020-05-21 IL IL274832A patent/IL274832A/en unknown
- 2020-09-16 AU AU2020233683A patent/AU2020233683A1/en not_active Abandoned
- 2020-09-25 US US17/033,195 patent/US20210008175A1/en not_active Abandoned
-
2021
- 2021-01-05 US US17/141,692 patent/US20210128696A1/en not_active Abandoned
-
2022
- 2022-01-20 JP JP2022007043A patent/JP2022058682A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2018121290A (ru) | Комбинации лизина бактериофага и антибиотика против грам-положительных бактерий | |
| Angelopoulou et al. | Non-antibiotic microbial solutions for bovine mastitis–live biotherapeutics, bacteriophage, and phage lysins | |
| Al Atya et al. | Anti-MRSA activities of enterocins DD28 and DD93 and evidences on their role in the inhibition of biofilm formation | |
| Huff et al. | Alternatives to antibiotics: utilization of bacteriophage to treat colibacillosis and prevent foodborne pathogens | |
| RU2018107249A (ru) | Применение лизина для восстановления/увеличения антибактериальной активности антибиотиков в присутствии легочного сурфактанта, который ингибирует указанные антибиотики | |
| Letrado et al. | Bactericidal synergism between antibiotics and phage endolysin Cpl-711 to kill multidrug-resistant pneumococcus | |
| ES2682670T3 (es) | Lisinas de bacteriófagos de Streptococcus para la detección y tratamiento de bacterias gram positivas | |
| Tagg | Prevention of streptococcal pharyngitis by anti-Streptococcus pyogenes bacteriocin-like inhibitory substances (BLIS) produced by Streptococcus salivarius | |
| AU2019222918B2 (en) | Antimicrobial peptides and methods of use thereof | |
| WO2015089073A3 (en) | Compositions and methods for phagocyte delivery of anti-staphylococcal agents | |
| RU2018102796A (ru) | Предотвращение, разрушение и обработка биопленки лизином бактериофага | |
| AU2016248363B2 (en) | Broad spectrum of streptococcus lyase and use thereof | |
| Ibrahim | Classification of antimicrobial peptides bacteriocins, and the nature of some bacteriocins with potential applications in food safety and bio-pharmaceuticals | |
| PH12013500264A1 (en) | Novel isolated bacteriophage having e. coli-specific bactericidal activity and antibacterial composition comprising the same | |
| RU2013117275A (ru) | Бактериофаги, фаговые пептиды и способы их применения | |
| BR112013005426A2 (pt) | "composto, composição, formulação farmacêutica, métodos para inibir uma enzima, para matar e/ou prevenir o crescimento de um micro-organismo, para tratar e/ou prevenir uma doença em um animal, e para inibir o domínio de edição de uma sintetase de t-rna, e, uso de um composto ou uma de combinação." | |
| RU2020104587A (ru) | Потенцирование компонентами крови антибактериальной активности литических белков, соответствующие способы и применения | |
| JP2020510024A5 (https=) | ||
| JP2013539776A5 (https=) | ||
| HRP20161439T1 (hr) | Uporaba helatirajućeg sredstva i peptidnih atimikrobnih spojeva | |
| JP2021513865A5 (https=) | ||
| Rahimzadeh et al. | Endolysins of bacteriophages as an anti-methicillin resistant staphylococcus aureus infection in children: a narrative review | |
| MX2018008545A (es) | Composicion antibacteriana y metodo para tratar infecciones por estafilococos con la composicion antibacteriana. | |
| WO2013041663A3 (de) | Modifizierte apidaecinderivate als antibiotische peptide | |
| NZ610400A (en) | Antimicrobial protein |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HE9A | Changing address for correspondence with an applicant |